Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes Sells 92,500 Shares

Denali Therapeutics Inc. (NASDAQ:DNLIGet Free Report) Director Steve E. Krognes sold 92,500 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the completion of the sale, the director now directly owns 47,341 shares of the company’s stock, valued at $970,490.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Denali Therapeutics Price Performance

Shares of DNLI opened at $19.38 on Wednesday. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of -17.94 and a beta of 1.33. Denali Therapeutics Inc. has a fifty-two week low of $15.45 and a fifty-two week high of $33.31. The business’s 50-day moving average is $18.85 and its 200-day moving average is $19.50.

Denali Therapeutics (NASDAQ:DNLIGet Free Report) last issued its earnings results on Tuesday, February 27th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.05). Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same period last year, the company posted ($0.75) earnings per share. Equities research analysts expect that Denali Therapeutics Inc. will post -2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently made changes to their positions in DNLI. Wellington Management Group LLP increased its holdings in Denali Therapeutics by 3.6% in the third quarter. Wellington Management Group LLP now owns 7,288,960 shares of the company’s stock worth $150,371,000 after buying an additional 250,784 shares during the last quarter. Gotham Asset Management LLC acquired a new position in Denali Therapeutics in the third quarter worth approximately $400,000. Eventide Asset Management LLC increased its holdings in Denali Therapeutics by 98.4% in the third quarter. Eventide Asset Management LLC now owns 621,850 shares of the company’s stock worth $12,829,000 after buying an additional 308,443 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Denali Therapeutics in the third quarter worth approximately $772,000. Finally, Capula Management Ltd acquired a new position in Denali Therapeutics in the third quarter worth approximately $799,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DNLI. HC Wainwright cut their price target on shares of Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Denali Therapeutics in a report on Wednesday, February 28th. The Goldman Sachs Group cut their price target on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Finally, Citigroup began coverage on shares of Denali Therapeutics in a research note on Wednesday, December 13th. They set a “buy” rating and a $32.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $44.67.

Check Out Our Latest Analysis on DNLI

Denali Therapeutics Company Profile

(Get Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Featured Articles

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.